Compare Adaptive Biotechnologies Corp (ADPT) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Peloton Interactive Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Peloton Interactive Inc trades at $5.78 (market cap $2.52B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | PTON | |
|---|---|---|
Market Cap | $3.33B | $2.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $9.00 |
52-Week Low | $10.24 | $3.71 |
Enterprise Value | $3.19B | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Peloton (PTON) trades at $5.82, up 1.22% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals, with operating cash flow turning positive to $333 million in 2025 and net losses narrowing significantly. Recent news highlights a potential turnaround, including inclusion in the S&P SmallCap 600 index and the appointment of a new CFO.
The outlook is cautiously optimistic as Peloton aims for profitability, but risks remain from high debt and revenue declines. Analyst consensus is a Buy with a $7.50 price target, suggesting 29% upside, though execution on growth initiatives is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
